Unsubscribe from email alerts. We are committed to providing leading innovations for today and the future that save and improve lives around the world. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. No Duty to Update The information contained in this website was current as of the date presented.
The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.
By continuing, you will be directed to a site intended only for residents of the United States and Canada. Sign up for email alerts. Related links. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Unsubscribe from email alerts. We are committed to providing leading innovations for today and the future that save and improve lives around the world.
There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. No Duty to Update The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.
By continuing, you will be directed to a site intended only for residents of the United States and Canada. Sign up for email alerts. Overall, Organon has more than 60 products, with the largest number and revenue from its established brands business. This portfolio includes brands beyond their patent loss in most markets, with only modest remaining loss-of-exclusivity exposure beyond , according to information from Merck as reported in May Under the agreement, Organon will gain exclusive worldwide rights to develop and commercialize ebopiprant.
In June June , Organon completed the acquisition of Alydia Health, a commercial-stage medical-device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage or abnormal postpartum uterine bleeding. Biosimilars is the third business area of Organon and currently consists of five biosimilar products see Figure 2 and formed from its collaboration with Samsung Bioepis, a joint venture between Samsung Biologics and Biogen.
Save my name, email, and website in this browser for the next time I comment. By Patricia Van Arnum. Share 0.
0コメント